本报告导读：依沃西将与辉瑞公司多款ADC药物开展联合疗法临床试验，目前依沃西已开展多项NSCLC全球临床，国际化布局持续提速。维持“增持”评级。投资要点：维持“增持”评级。卡度尼利、依沃西双双新纳入医保，放量可期。海外临床布局持续深化，核心产品加速迎来收获期；维持2024-2026年收入预测26.30/39.13/58.82亿元，维持“增持”评级。依沃西将与辉瑞公司多款ADC药物开展联合疗法...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.